Skip to Main Content

Paper Details

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
Nat Commun
39
2022
KRAS, KRAS mutation, KRAS wildtype tumors, PDAC, circulating tumor DNA, ctDNA, gemcitabine, lymphocytes, mPDAC, metastatic pancreatic ductal adenocarcinoma, mismatch repair deficiency, nab-, nab-paclitaxel, paclitaxel, patient, patients, tremelimumab

Datasets

Release 1.2